BFM
DRUG

Boothbay Fund Management’s Bright Minds Biosciences DRUG Stock Holding History

Boothbay Fund Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
27,870
-23,420
-46% -$1.84M 0.03% 734
2026
Q1 		$3.74M Buy
51,290
+3,800
+8% +$306K 0.05% 400
2025
Q4 		$3.71M Buy
47,490
+19,371
+69% +$1.29M 0.06% 386
2025
Q3 		$1.71M Buy
28,119
+8,955
+47% +$348K 0.02% 629
2025
Q2 		$500K Hold
19,164
– – 0.01% 902
2025
Q1 		$691K Sell
19,164
-25,416
-57% -$930K 0.02% 750
2024
Q4 		$1.61M Buy
+44,580
New +$1.57M 0.04% 496
2022
Q3 		– Sell
-2,208
Closed -$9K – 2322
2022
Q2 		$9K Hold
2,208
– – ﹤0.01% 2197
2022
Q1 		$17K Hold
2,208
– – ﹤0.01% 2227
2021
Q4 		$35K Buy
+2,208
New +$49.1K ﹤0.01% 1790

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Boothbay Fund Management's DRUG Position: Q2 2026 in Review

Boothbay Fund Management reduced its Bright Minds Biosciences (DRUG) stake by 46% in Q2 2026, selling an estimated $1.84M and leaving 27,870 shares worth $1.96M. The position accounts for 0.03% of the portfolio, ranked #734.

Boothbay Fund Management first reported a position in DRUG in Q4 2021 and has held it in 10 quarters since. The position peaked at $3.74M in Q1 2026. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Boothbay Fund Management held 27,870 shares of Bright Minds Biosciences worth $1.96M as of Q2 2026.
  • Boothbay Fund Management sold 23,420 Bright Minds Biosciences shares in Q2 2026, an estimated $1.84M.
  • Bright Minds Biosciences made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #734 holding.
  • Boothbay Fund Management first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 10 quarters since.
  • Boothbay Fund Management's Bright Minds Biosciences position peaked at $3.74M in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.